Clinical trial NCT00493805: Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
Official title: Study to Evaluate Response Rates in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Hepatitis C, Chronic
Insulin Resistance
Keywords: homeostasis model assessment of insulin resistance
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-06-28
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1. The study consists of two parts: (1) a noninterventional arm (HOMA IR \<= 2) and (2) an interventional arm (HOMA IR \> 2), where HOMA IR is the insulin resistance index for the participants calculated by fasting insulin (uU/mL) x \[fasting glucose (mmol/L)/22.5\]. Participants in the noninterventional arm are treated according to the European labeling and response rates are evaluated at Month 1 (optional), 3, 6, 12, and follow up. Participants in the interventional arm are treated with PEG-Intron 1.5 ug/kg (subcutaneous) once weekly plus weight-based REBETOL 800-1400 mg (oral capsules) daily for a variable period depending on their response at Week 12: (1) HCV-RNA positive with \< 2-log drop in viral load, treatment will be discontinued; (2) HCV-RNA positive with \>= 2-log drop in viral load; participants will be randomized (1:1) to Group A (stop treatment at Week 48) or Group B (stop treatment at Week 72); and (3) HCV-RNA negative, treatment will be changed to be according to the European labeling and response rates will be evaluated at Month 6, 12, and follow up. All participants will go on with their treatment after Week 12 until the results of the HCV polymerase chain reaction (PCR) are available (maximum of 4 weeks).


Eligibility criteria: Inclusion Criteria:

* male and female participants with newly diagnosed chronic hepatitis C
* age 18-65
* HCV-RNA positive in serum as measured by PCR
* Genotype 1
* ALT levels according to European labeling
* in women of child-bearing age, pregnancy must be excluded prior to entry into the study, and the use of a safe contraceptive device must be documented; sexually active male participants must practice a method of contraception considered acceptable (vasectomy, condom plus spermicide, plus relationship with a female partner who practices an acceptable method of contraception)
* Lab parameters:

  * Hb: \>=12 g/dL (women) or \>= 13 g/dL (men)
  * leukocytes \>= 3,000/µL
  * thrombocytes \>= 100,000/µL
  * PT/PTT/coagulation must be within normal limits or clinically acceptable to the investigator/sponsor
  * Albumin must be within normal limits or clinically acceptable to the investigator/sponsor
  * creatinine must be within normal limits or clinically acceptable to the investigator/sponsor
  * uric acid must be within normal limits or clinically acceptable to the investigator/sponsor
* antinuclear antibodies \<= 1:160
* signed informed consent

Exclusion Criteria:

* refusal by women of child-bearing age or by sexually active participants to use a safe contraceptive
* breast-feeding women
* cirrhosis stage B and C according to Child-Pugh
* signs of decompensated liver disease
* confirmed co-infection with HIV or HBV
* existing psychiatric comorbidity
* alcohol abuse
* active malignant disease or suspicion or history of malignant disease within 5 previous years (except for adequately treated basal cell carcinoma)
* existing psoriasis or other dermatological disorder
* treatment with a study drug within the last 30 days
* any uncontrolled underlying medical conditions
* clinically significant ECG abnormalities and/or significant cardiovascular dysfunction within the last 6 months. In case of other suspected heart disease, a cardiological examination is required.
* any liver disorder of other genesis than the study indication (with regard to elevated iron levels, only participants with manifest hemochromatosis are excluded)
* autoimmune disorder (except LKM-positive participants).

Primary outcomes:
measure: Early Virological Response in Participants With and Without Insulin Resistance
timeFrame: At Week 12 (after start of therapy)
Secondary outcomes:
measure: Sustained Virological Response (PCR 24 Weeks After End of Treatment)
timeFrame: Up to 24 weeks following 48 or 72 weeks of therapy
Other outcomes:
Locations:
Study officials:
References: